Please assess the completion status of the following clinical trial:

Trial Title: A Phase III Trial Evaluating Fruquintinib Efficacy and Safety in 3+ Line Colorectal Cancer Patients （FRESCO)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* ≥ 18 and ≤ 75 years of age , with ≥ 40Kg~* Histological or cytological confirmed colorectal cancer~* ECOG performance status of 0-1~* Standard regimen failed or no standard regimen available~* Adequate hepatic, renal, heart, and hematologic functions~* At least one measurable lesion (larger than 10 mm in diameter by spiral CT scan)~* Signed and dated informed consent~* Willingness and ability to comply with scheduled visits, treatment plans, laboratory tests, and other study procedure~Exclusion Criteria:~* - Pregnant or lactating women~* Any factors that influence the usage of oral administration~* Evidence of CNS metastasis~* Intercurrence with one of the following: non-controlled hypertension, coronary artery disease, arrhythmia and heart failure~* Abuse of alcohol or drugs~* Less than 4 weeks from the last clinical trial - Previous treatment with VEGFR inhibition~* Disability of serious uncontrolled intercurrence infection~* Proteinuria ≥ 2+ (1.0g/24hr)~* Have evidence or a history of bleeding tendency within two months of the enrollment, regardless of seriousness~* Within 12 months before the first treatment occurs artery/venous thromboembolic events, such as cerebral vascular accident (including transient ischemic attack) etc.~* Within 6 months before the first treatment occurs acute myocardial infarction, acute coronary syndrome or CABG~* Bone fracture or wounds that was not cured for a long time~* Coagulation dysfunction, hemorrhagic tendency or receiving anticoagulant therapy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- treatment arm (Type: ACTIVE_COMPARATOR): treatment arm- subjects will receive Fruquintinib 5mg orally, QD, plus BSC for 3 wks on/ 1 wk off. Patients will receive a cycles of 4 weeks of study treatment (1 cycle of study treatment includes 3 weeks of treatment and 1 week of drug discontinuation) or until the occurrence of progressive disease (PD), death, unacceptable toxicity, withdrawal of consent or other conditions that meet the end of treatment criteria.
- control arm (Type: PLACEBO_COMPARATOR): control arm- subjects will receive Fruquintinib placebo 5mg orally, QD, plus BSC for 3 wks on/ 1 wk off. Patients will receive a cycles of 4 weeks of study treatment (1 cycle of study treatment includes 3 weeks of treatment and 1 week of drug discontinuation) or until the occurrence of progressive disease (PD), death, unacceptable toxicity, withdrawal of consent or other conditions that meet the end of treatment criteria.

Based on this trial design, predict the completion outcome and termination type (if applicable).